Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

D-Pharm submits IND and SPA to FDA for phase III trial of DP-b99 in acute stroke

May 8, 2009

AcelRx commences phase II clinical trial of ARX-01 Sufentanil NanoTab PCA System

May 8, 2009

Merck initiates phase III SETTLE trial of safinamide in Parkinson's disease

May 8, 2009

Novel compounds for the treatment of pain discovered by Daiichi Sankyo

May 8, 2009

Novel antimigraine compounds claimed by Lilly

May 7, 2009

Mycophenolate mofetil may be used in patients with chronic inflammatory demyelinating polyneuropathy

May 7, 2009

FDA grants marketing approval to Vanda's Fanapt for schizophrenia

May 7, 2009

Butylphthalide lessens stroke impact in clinical study

May 7, 2009

AX-200 begins phase II efficacy trial for acute ischemic stroke

May 6, 2009

Ingenium claims novel CDK9 inhibitors that function as analgesics

May 6, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...